CNS Pharmaceuticals annual debt-to-equity ratio
2019
2020
2022
2024
2025
CNS Pharmaceuticals Debt-to-Equity Ratio Growth & History (CNSP)
CNS Pharmaceuticals's debt-to-equity ratio was 0.07 for fiscal 2025.
View full CNS Pharmaceuticals company overviewCNS Pharmaceuticals annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.07 | 0.02 | +37.61% |
| 2024 | 2024-12-31 | 0.05 | — | — |
| 2022 | 2022-12-31 | 0.05 | — | — |
| 2020 | 2020-12-31 | 0.03 | 0.03 | — |
| 2019 | 2019-12-31 | 0.00 | — | — |
CNS Pharmaceuticals quarterly debt-to-equity ratio
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | 3.27 | 3.25 | +16940.71% |
| Q4 2025 | 2025-12-31 | 0.07 | — | — |
| Q3 2025 | 2025-09-30 | 0.00 | — | — |
| Q2 2025 | 2025-06-30 | 0.01 | — | — |
| Q1 2025 | 2025-03-31 | 0.02 | — | — |
| Q4 2020 | 2020-12-31 | 0.03 | 0.03 | — |
| Q3 2020 | 2020-09-30 | 0.00 | −1,388.89 | — |
| Q2 2020 | 2020-06-30 | 0.00 | — | — |
| Q1 2020 | 2020-03-31 | 0.00 | — | — |
| Q4 2019 | 2019-12-31 | 0.00 | — | — |
| Q3 2019 | 2019-09-30 | 1,388.89 | — | — |
CNS Pharmaceuticals debt-to-equity ratio trends
Over the last five fiscal years, CNS Pharmaceuticals's debt-to-equity ratio increased from 0.03 to 0.07, a change of 0.04. The latest reported quarter, Q1 2026, shows 3.27.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CNS Pharmaceuticals source filings ↗